Global HealthQ2 FY25

Global Health Q2 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,444.2P/E: 60.0Market Cap: ₹38.8K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • The company expects continued robust volume-driven growth, supported by increased bed capacity and expanded clinical capabilities, especially in developing hospitals like Lucknow and Patna.
  • Expansion includes capacity addition: 280 beds added in H1 FY25 (150 in Lucknow, 84 in Patna, 50 in Gurugram), with focus on ramping up occupancy.
  • Introduction of advanced technology, e.g., Da Vinci Xi Surgical Robot, aims to improve patient outcomes and attract more patients.
  • Matured hospitals show steady revenue growth: 13.5% YoY in Q2 FY25; developing hospitals growing at 4.2% YoY.
  • International patient revenue is currently around 6%, expected to grow as new NCR facilities come online, though subject to geopolitical risks.
  • Focus remains on sustainable, ethical growth by strengthening existing services and expanding reach into new areas.
  • Pipeline projects including new facilities in Pitampura, Mumbai, and Noida expected to contribute incrementally over 3-4 years.

See what Global Health management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of current or future fundraising through debt or equity in the transcript.
  • The focus is on ongoing and planned capex for various projects (New facilities in Pitampura, Mumbai, Medical School, Guest House) to be funded over the next three to four years.
  • Mention of capital inflow in the healthcare industry post-COVID and increased interest from the financial community in building hospitals, but no direct statement about Medanta raising funds.
  • The company emphasizes sustainable and ethical growth with a long-term view, not radical or short-term capital raising.
  • CFO Yogesh Kumar Gupta mentions capex plans but does not detail any planned fundraising.
  • Overall, the discussion centers more around strategic investments and capex management rather than immediate fundraising plans.

See what Global Health management said on order book — free account, 30 seconds.

Capex plans

Yes
  • INR 300 crores budgeted for medical school build-out (4-5 lakh sq ft) on 25 acres hospital campus; timeline 3-4 years.
  • Ongoing Pitampura project (Delhi) with DLF partnership; delayed due to pollution clearances but fully on track.
  • Indore project currently delayed and stuck in litigation; exploring alternative expansion options.
  • South Delhi project delayed due to compliance and approval issues.
  • Mumbai land acquisition completed; part of INR 370 crores capex in H1 FY25.
  • Total capex guidance: ~INR 470 crores on existing units and INR 500 crores for Noida project over next 3-4 years.
  • Major medical equipment purchases aligned with hospital development phases.
  • Focus on expanding capacity (e.g., 118 beds added in Q2 FY25 at Lucknow and Patna).
  • Commitment to sustainable, ethical growth and strengthening existing facilities alongside new expansions.

Track Global Health — get its next earnings analysis in your feed

How does Global Health rank vs peers in Healthcare Services?

Pro feature
ThisGlobal Health
Rev 3Mar 3

How does Global Health rank in Healthcare Services?

Compare Global Health against every Healthcare Services company (Q2 FY25) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Others in Healthcare Services this season

  • Chandan Healthca (Q2 FY27)

    Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor

  • Invicta Diagnostic (Q2 FY27)

    Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2

  • Unihealth Hosp (Q2 FY27)

    1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r

  • Sangani Hospital (Q2 FY27)

    1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →